Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Mitapivat in Moderate Hepatic Impairment
NCT05610657Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Jan 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitapivat in pyruvate kinase deficiency (PKD), sponsored by Agios Pharmaceuticals. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity, Area Under the Plasma Concentration-Time Curve From Time 0 to Last Quantifiable Concentration and 1 more. Started Jan 2023; status: completed.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on NCT05610657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05610657.